

**THE FOLLOWING CONCORDANCE TABLE ENABLES THE MAIN INFORMATION STIPULATED BY THE FINANCIAL REPORT INDICATED IN ARTICLE L.451-1-2 OF THE FRENCH MONETARY AND FINANCIAL CODE AND ARTICLE 222-3 OF THE AMF GENERAL REGULATIONS TO BE IDENTIFIED**

Headings/Themes	Section(s)	Page(s)
Parent company financial statements	6.2.1	203
Consolidated financial statements	6.1.1	144
Management report	See concordance table between the Registration Document and the management report	
Statement by the person responsible for the annual financial report	8.1.2	268
Statutory Auditors' report on the parent company financial statements	6.2.4	240
Statutory Auditors' report on the consolidated financial statements	6.1.3	200

**THE CONCORDANCE TABLE HEREAFTER INCLUDES ALL THE ELEMENTS FROM THE MANAGEMENT REPORT REQUIRED BY ARTICLES L. 225-100 ET SEQ., L. 232-1, II, L. 233-26 AND R. 225-102 OF THE FRENCH COMMERCIAL CODE**

Themes	Section(s)	Page(s)
<b>I. Activity</b>		
Objective and exhaustive review of the change in business, the results and financial position of the Company and the Group, in particular its indebtedness, in view of its volume and the complexity of its activities	5.1 / 5.2 / 6.2.3	132 / 133 / 235
Position of the Company and the Group during the last financial year	5.2.2 / 5.5.1 / 5.5.2 / 6.2.3.1	135 / 140 / 140 / 235
Forecast changes for the Company and Group	5.6.2	141
Significant events for the Company and Group after the year end	5.6.1	141
Research & development activities of the Company and the Group	1.6.1	41
List of existing branches	1.4.2	37
Investments in companies with their registered offices on the French Republic's territory	1.4.2	37
Activities and results for the Company, its subsidiaries and companies over which it has control	5.2 / 6.2.2 (Note 4.3.3)	133 / 213
Key performance indicators of a financial and, where relevant, non-financial nature, related to the specific activities of the Company, particularly information on environmental and staff issues with reference to the amounts in the annual financial statements and any additional relevant explanations.	5.2/3.2 to 3.4	133 / 71
<b>II. Risk factors</b>		
Principal risks and uncertainties to which the Company and Group are exposed	2	51
Company and Group objectives and policy in terms of financial risk management, including the hedging policy	2.4	62
Indications about financial risks related to the effect of climate change and presentation of measures taken by the Company to reduce them whilst implementing a low-carbon strategy in all aspects of its activities	2.1.11.1 / 3.4.2.3	57 / 90
Main characteristics of the internal control and risk management procedures relating to the preparation and processing of financial and accounting information	4.4.1	125
Company and Group exposure to price, credit, liquidity and cash flow risks	2.4	62
<b>III. Legal and shareholder information</b>		
Identity of individuals or companies holding, directly or indirectly, over 5% of the share capital or voting rights	7.4.1	253
Modifications that have occurred during the year	7.4.1	253
Name of companies controlled and share of the Company's share capital that they hold (treasury shares)	1.4.2 / 6.2.1 (note 4.3.3)	37 / 213
Number of shares purchased and sold during the financial year, average purchase and sale price, level of fees and commissions, number of shares registered in the Company's name at the end of the financial year and their value at the purchase price and at nominal value, reasons for acquisitions carried out and fraction of the share capital that they represent	7.3.2	248
Calculation elements and results of any adjustments for conversion bases and conditions for subscribing or exercising securities giving access to the share capital or stock options or share buybacks for securities giving access to the share capital in the event of share buy backs or financial transactions	7.3.3	250
stake of employees (and any executives) in the share capital on the last day of the financial year and proportion of the share capital owned by employees and managed collectively (PEE or FCPE) and registered shares owned directly by them under a share grant plan or other schemes (share ownership plans, privatisations etc.)	7.4.3	254

Themes	Section(s)	Page(s)
Special report on transactions carried out by the Company or companies connected to it related to the allocation of free shares to employees and executives	7.4.3.2	254
Special report on transactions by the Company or companies connected to it under stock option plans restricted to employees and executives	7.4.3.2	254
<b>IV. Financial information</b>		
Table indicating the Company's results over the last five financial years	6.2.3.3	237
Changes in the presentation of the annual financial statements and valuation methods used	N/A	
Information on payment periods of trade payables and trade receivables of the Company the annual financial statements of which are certified by a Statutory Auditor	6.2.3.4	238
Amount of dividends distributed during the last three financial years and the amount of net revenues distributed eligible for the deduction as well as the amount of those that are not, broken down by share category	7.6	259
Amount of inter-company loans (loans with terms of less than 2 years to micro-companies, SMEs and ETIs with which the Company has economic links that justify them)	N/A	
Information on the acquisition by the Company of treasury shares for the purpose of allocating them to the employees or directors	7.3.2.1 / 7.3.2.2	248 / 250
Restrictions imposed by the Board of Directors on exercising options granted or the sale of shares allocated to executives free of charge	4.3.2.1 / 7.4.3.2	117 / 254
Conditions for the conservation of free shares granted to executive corporate officers	4.3.2.1 / 7.4.3.2	117 / 254
Breakdown of trading in the Company's shares by senior executives, senior managers or by their close relations	7.4.5.2	257
<b>VI. Information on Corporate Social Responsibility</b>		
Human resources	3.1 / 3.3 / 3.5	66 / 77 / 95
Environment information	3.1 / 3.4 / 3.5	66 / 87 / 95
Information on corporate commitments to promote sustainable development	3.1 / 3.2 / 3.5	66 / 71 / 95
Information for companies operating at least one installation on the list stipulated in article L.515-36 of the French Environment Code	2.2	60



## THE CONCORDANCE TABLE HEREAFTER CONTAINS THE INFORMATION REQUIRED IN APPLICATION OF ARTICLES L.225-102-1 PARAGRAPH 5 AND R.225-105-1 OF THE FRENCH COMMERCIAL CODE

Headings/Themes	Section(s)	Page(s)
<b>1° Human resources</b>		
<b>a) Workforce</b>		
• total workforce and breakdown of employees by gender, age and geographic area	3.3.1.1 / 3.3.1.2 / 3.3.1.6 / 3.3.1.7 to 3.3.1.9	77 / 77 / 78 / 79
• recruitments and dismissals	3.3.1.3 to 3.3.1.5	77
• compensation and pay increases	3.3.6	86
<b>b) Work organisation</b>		
• working time organisation	3.3.5.1	84
• absenteeism	3.3.1.10	79
<b>c) Employee relations</b>		
• the organisation of social dialogue, specifically employee information, consultation and negotiation procedures	3.3.5	84
• the overview of collective agreements	3.3.5	84
<b>d) Health and safety</b>		
• occupational health and safety conditions	3.3.2	80
• the overview of the agreements signed with trade unions or employee representatives on occupational health and safety	3.3.5.1	84
• occupational accidents, including their frequency and severity, as well as occupational diseases	3.3.2.4	81
<b>e) Training</b>		
• training implementation policies	3.3.3.2	81
• the number of training hours	3.3.3.2	81
<b>f) Equal treatment</b>		
• measures to promote gender equality	3.3.5.2	85
• measures to promote the employment and integration of disabled employees	3.3.4.2	84
• policy to fight discrimination	3.3.5.2 / 3.3.7	85 / 86
<b>g) Promotion of and compliance with the International Labour Organization's Core Conventions</b>		
• respect for the freedom of association and the right to collective bargaining	3.3.7	86
• the elimination of discrimination in employment and occupations	3.3.7	86
• the elimination of forced or compulsory labour	3.3.7	86
• the effective abolition of child labour	3.3.7	86
<b>2° Environmental information</b>		
<b>a) Environmental policy</b>		
• the Company's organisation to take into account environmental issues, and if required, the environmental assessment or certification procedures	3.4.1	87
• employee training and information on environmental protection	3.4.1	87
• the means implemented to prevent environmental risks and pollution	3.4.2	87
• the amount of provisions and guarantees for risks to the environment, provided that such information is not likely to cause serious harm to the Company in ongoing litigation	2.1.12	59
<b>b) Pollution</b>		
• measures related to the prevention, reduction or repair of damage caused by discharges in the air, water and soil seriously affecting the environment	3.4.2.5	93
• accounting for noise pollution and all other forms of activity-specific pollution	3.4.3	93
<b>c) Circular economy</b>	<b>3.1.2 / 3.4.1</b>	<b>66 / 87</b>
<b>i. Waste prevention and management</b>		
• measures related to the prevention, recycling, reuse and other forms of recovery and disposal of waste	3.4.2.4	91
• actions to fight against food waste	3.4.2.4	92

Headings/Themes	Section(s)	Page(s)
<b>ii. Sustainable use of resources</b>		
• water consumption and supply in compliance with local restrictions	3.4.2.1	87
• the consumption of raw materials and the measures taken to improve efficiency in their use	3.4.2.8	93
• energy consumption, measures taken to improve energy efficiency and the use of renewable energies	3.4.2.2	89
• land use	3.4.2.7	93
<b>d) Climate change</b>		
• significant greenhouse gas emissions categories generated by the Company's business, particularly through the use of the goods and services that it produces	3.4.2.3	90
• adapting to the consequences of climate change	3.4.2.3	90
<b>e) Protecting biodiversity</b>		
• measures taken to preserve or encourage biodiversity	3.4.4	94
<b>3° Information on corporate commitments to promote sustainable development</b>		
<b>a) Territorial, economic and social impact of the Company's business</b>		
• in terms of employment and regional development	3.1.4.2 / 3.2.2.4 / 3.2.3.2	69 / 75 / 76
• on neighbouring or local populations	3.1.4.2 / 3.2.2.4	69 / 75
<b>b) Relationships with stakeholders, particularly associations to combat social exclusion, teaching establishments, environmental protection associations, consumer associations and local populations</b>		
• conditions of dialogue with these persons or organisations	3.1.4	69
• partnership or sponsorship activities	3.1.4.3 / 3.2.2	70 / 72
<b>c) Subcontracting and suppliers</b>		
• integrating social and environmental issues into the purchasing policy	3.2.3	75
• the importance of subcontracting and integrating labour-related and environmental concerns into the Company's relationship with its suppliers and subcontractors	3.2.3	75
<b>d) Fair trade</b>		
• actions taken to prevent corruption	3.1.3	67
• measures to promote consumer health and safety	3.1 / 3.2	66 / 71
<b>e) Other initiatives taken under section 3 to promote human rights</b>	<b>3.1.1 / 3.1.3 / 3.3.7</b>	<b>66 / 67 / 86</b>

**THE CONCORDANCE TABLE HEREAFTER INCLUDES ALL THE DATA FROM THE MANAGEMENT REPORT ON CORPORATE GOVERNANCE REQUIRED BY ARTICLES L. 225-37-2 TO L. 225-37-5 AND L. 225-100**

Theme	Section(s)	Page(s)
<b>I. Corporate Governance Code</b>		
Declaration of conformity with the corporate governance regime in force in France, where the code can be consulted and any rules that exceed the minimum legal requirements	4.1	102
<b>II. Composition and organisation of the work of the Board of Directors</b>		
Body chosen to exercise the Company's general management functions (Chair of the Board of Directors or Chief Executive Officer)	4.2.1	103
Any restrictions placed by the Board of Directors on the Chief Executive's powers	4.2.1 / 4.2.3.1	103 / 110
List of all directorships and positions in any company exercised by all of these officers over the course of the financial year	4.2.2.1	104
Conflicts of interest at the administrative, management and supervisory bodies and executive management level	4.2.2.3	109
Committees of the Board / Composition and conditions for preparing and organising the work of the Board and application of the principle of gender equality	4.2.2.4 / 4.2.3	109 / 110
Service agreements linking members of the administrative or management bodies to the issuer or any of its subsidiaries and providing for the payment of benefits	7.7.2 to 7.7.4	260
Agreements, directly or by a third party, between on the one hand, and depending on the situation, one of the members of the Management Board or Supervisory Board, the Chief Executive Officer, one of the Chief Operating Officers, one of the directors or one of the shareholders with a share of voting rights over 10% in a company, and on the other hand, another company in which the person owns, directly or indirectly, over half the share capital	7.7.2 to 7.7.4	260
Summary table of valid delegations granted by the Shareholders' Meeting to the Board of Directors or Management Board in the area of capital increases and the use made of these delegations during the year	7.3.4	251



Theme	Section(s)	Page(s)
Specific arrangements relating to shareholders' attendance at the Annual General Meeting or reference to the provisions in the bylaws that set out these arrangements	7.2.5	248
Factors likely to have an impact in the event of a public offer	7.5	258
<b>III. Compensation of senior executives and corporate officers</b>		
Total compensation and benefits-in-kind paid during the financial year to each corporate officer by the Company, the companies it controls or the company that controls it	4.3	114
Commitments of all types made by the Company for the benefit of its corporate officers, corresponding to compensation, indemnities or benefits due or likely to be due in connection with their appointment, termination or change of office or subsequent thereto, particularly post-employment benefit obligations and other lifetime benefits	4.3.3	124
Principles and criteria for the determination, distribution and allocation of fixed, variable and exceptional items making up the total compensation and benefits-in-kind, due to the Chairman, Chief Executive Officers or Chief Operating Officers, Chief Executive Officers or Chief Operating Officers	4.3.2.1	116
Amount of compensation paid and benefits-in-kind for members of the administrative, management and supervisory bodies	4.3.2.2 / 4.3.2.3	118 / 120
Draft resolutions drawn up by the Board of Directors for the approval of the principles and criteria for determining, distributing and awarding the fixed, variable and exceptional components that make up total compensation and any benefits to the Chairmen and Chief Executive Officers and Chief Operating Officers by virtue of their office (say on pay)	4.3.2	115
Variable or exceptional compensation awarded over the course of the elapsed financial year to those executives	4.3.2.2	118
Total amounts provisioned or recognised by the issuer or its subsidiaries for the payment of pensions, retirement or other benefits	4.3.5	125

## 8.6 Glossaries

### 8.6.1 Scientific terms

**Nucleic acid:** Nucleic acid is a naturally-occurring molecule found in most cells. It has the ability to hold and transmit coded hereditary instructions allowing for an organism's development. There are two types of nucleic acids: DNA and RNA.

**Amplification:** a technique, usually using enzymes, for multiplying nucleic acids in order to increase the sensitivity of detection methods.

**Antibiotic susceptibility test:** an analysis to determine the sensitivity of a bacterium to antibiotics.

**Antibiotic:** a substance of natural or synthetic origin capable of stopping the multiplication of bacteria.

**Antibody:** a complex protein molecule produced by the immune system to detect and neutralise disease-causing organisms, in particular viruses.

**Antigen:** a macromolecule recognised by an antibody or cells from an organism's immune system that triggers an immune response.

**DNA:** the acronym of "deoxyribonucleic acid". These nucleotides consist of a sugar (deoxyribose), a phosphate group and one of the following nitrogen-containing bases: adenine (A), cytosine (C), guanine (G) or thymine (T), and serve as a medium for genetic information.

**ANSM (Agence nationale de sécurité du médicament et des produits de santé):** French regulatory agency, which carries out assessments, provides expertise and makes decisions regarding the safety of drugs and healthcare products.

**ANVISA (Agência Nacional de Vigilância Sanitária):** Brazilian agency responsible for regulating food and medical products.

**RNA:** the acronym of "ribonucleic acid". A polymer similar to DNA which, like DNA, mainly has a role as a vector of genetic information. The sugar in RNA is a ribose.

**Bacterium:** a unicellular microorganism lacking chlorophyll and visible only under a microscope. Bacteria do not belong to either the plant or the animal kingdom.

**Multi-resistant bacteria:** bacteria are said to be multi-resistant to antibiotics when they are sensitive only to a small number of the antibiotics customarily used in therapy, as a consequence of the accumulation of natural and acquired resistances.

**Biochemistry:** an area of science which studies the correlation between the structure of natural molecules and the consequences on their activity.

**Molecular biology:** technology that analyses genetic sequences of DNA or RNA that are characteristic of a bacterium, virus, protein or cell.

**CFDA (China Food and Drug Administration):** Chinese agency responsible for regulating food and medical products.